Cargando…

Personalized Antiplatelet Therapy Based on CYP2C19 Genotypes in Chinese ACS Patients Undergoing PCI: A Randomized Controlled Trial

Background: The clinical benefits of cytochrome P450 (CYP) 2C19 genotype-guided antiplatelet therapy in Asians remain unclear. In this study, we aimed to investigate the clinical outcomes of pharmacogenomic antiplatelet therapy in Chinese patients. Methods: Patients with acute coronary syndrome plan...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shi, Xiujin, Zhang, Yunnan, Zhang, Yi, Zhang, Ru, Lin, Baidi, Han, Jialun, Li, Wenzheng, Fang, Zhenwei, Yan, Jialin, Wang, Yifan, Zheng, Ze, Lv, Yuan, Lin, Yang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Cardiovascular Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8242578/ https://www.ncbi.nlm.nih.gov/pubmed/34222372 http://dx.doi.org/10.3389/fcvm.2021.676954

Ejemplares similares

Efficacy and Safety of Prolonged Dual Antiplatelet Therapy after Percutaneous Coronary Intervention in Acute Coronary Syndrome Patients
por: Han, Jialun, et al.
Publicado: (2023)

Ticagrelor vs. Clopidogrel in Older Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: Insights From a Real-World Registry
por: Zhang, Yunnan, et al.
Publicado: (2022)

Prolonged dual antiplatelet therapy for Chinese ACS patients undergoing emergency PCI with drug-eluting stents: Benefits and risks
por: Zhang, Yong, et al.
Publicado: (2023)

Sex-related differences in clinical outcomes and predictive factors in the very elderly patients with ACS undergoing PCI
por: Wang, Jia-li, et al.
Publicado: (2022)

Clinical efficacy and safety of tirofiban combined with conventional dual antiplatelet therapy in ACS patients undergoing PCI
por: Guo, Yong-zhe, et al.
Publicado: (2021)

Individualising dual antiplatelet therapy after percutaneous coronary intervention: the IDEAL-PCI registry
por: Christ, Günter, et al.
Publicado: (2014)

Evaluation of race and ethnicity disparities in outcome studies of CYP2C19 genotype-guided antiplatelet therapy
por: Nguyen, Anh B., et al.
Publicado: (2022)

Bedside testing of CYP2C19 gene for treatment of patients with PCI with antiplatelet therapy
por: Al-Rubaish, Abdullah M., et al.
Publicado: (2020)

Role of tirofiban with dual antiplatelet therapy in patients with STEMI undergoing primary PCI
por: Türker, Yasin
Publicado: (2016)

Prognosis of Atrial Fibrillation Patients Undergoing PCI According to Anticoagulants and Antiplatelet Agents
por: Yoon, Gwang-Seok, et al.
Publicado: (2021)

Long-term follow-up results in patients undergoing percutaneous coronary intervention (PCI) with drug-eluting stents: results from a single high-volume PCI centre
por: Yao, Hai-Mu, et al.
Publicado: (2014)

Tailored Antiplatelet Therapy in Patients Undergoing PCI: Is Rapid Bedside Genetic Testing the Answer?
por: Faxon, David P.
Publicado: (2020)

Influence of CYP2C19 genetic variants and smoking on dual antiplatelet efficacy in patients with coronary artery disease
por: Cheng, Yujing, et al.
Publicado: (2023)

Is the duration of dual antiplatelet therapy (DAPT) excessive in post-angioplasty in chronic coronary syndrome? Data from the France-PCI registry (2014–2019)
por: Mezier, A., et al.
Publicado: (2023)

CYP2C19 genotype and platelet aggregation test-guided dual antiplatelet therapy after off-pump coronary artery bypass grafting: A retrospective cohort study
por: Yao, Haoyi, et al.
Publicado: (2022)

Variants of PEAR1 Are Associated With Outcome in Patients With ACS and Stable CAD Undergoing PCI
por: Stimpfle, Fabian, et al.
Publicado: (2018)

Treatment Outcomes of Clopidogrel in Patients With ACS and Diabetes Undergoing PCI-Analysis of Beijing Municipal Medical Insurance Database
por: Wang, Weihao, et al.
Publicado: (2021)

Low-dose and standard-dose ticagrelor compared with clopidogrel in patients with acute coronary syndromes: A cohort study from china
por: Peng, Wenxing, et al.
Publicado: (2022)

Factors associated with health-related quality of life in patients undergoing percutaneous coronary intervention: Thai PCI registry
por: Siriyotha, Sukanya, et al.
Publicado: (2023)

CYP2C19 genotype-guided antiplatelet therapy: promises and pitfalls
por: Ellithi, Moataz, et al.
Publicado: (2020)

Optimising PCI by Intracoronary Image-guidance
por: Alasnag, Mirvat, et al.
Publicado: (2022)

An analysis of patients receiving emergency CAG without PCI and the value of GRACE score in predicting PCI possibilities in NSTE-ACS patients
por: Zhou, Bo-Da, et al.
Publicado: (2015)

Impact on percutaneous coronary intervention for acute coronary syndromes during the COVID-19 outbreak in a non-overwhelmed European healthcare system: COVID-19 ACS-PCI experience in Ireland
por: Connolly, Niall Patrick, et al.
Publicado: (2021)

Dual Antiplatelet Therapy vs. Single Antiplatelet Therapy After Transcatheter Aortic Valve Replacement: An Updated Systematic Review and Meta-Analysis
por: Zhang, Yipeng, et al.
Publicado: (2021)

The value of Sonoclot detection technology to guide the clinical medication of the perioperative anticoagulation and antiplatelet therapy in patients with acute myocardial infarction undergoing emergent PCI
por: Yang, Wu-Xiao, et al.
Publicado: (2017)

Prehospital and in-hospital delays to care and associated factors in patients with STEMI: an observational study in 101 non-PCI hospitals in China
por: Feng, Lin, et al.
Publicado: (2019)

Association of Derived Neutrophil-To-Lymphocyte Ratio With Prognosis of Coronary Heart Disease After PCI
por: Liu, Gang-Qiong, et al.
Publicado: (2021)

Effects of different CYP2C19 genotypes on prognosis of patients complicated with atrial fibrillation taking clopidogrel after PCI
por: Zhang, Qifeng, et al.
Publicado: (2018)

Duration of Dual Antiplatelet Therapy After Implantation of Drug-Coated Balloon
por: Zhang, Yuxuan, et al.
Publicado: (2021)

Combination of TyG Index and GRACE Risk Score as Long-Term Prognostic Marker in Patients with ACS Complicated with T2DM Undergoing PCI
por: Qin, Zhen, et al.
Publicado: (2022)

Evaluating the Extent of Reusability of CYP2C19 Genotype Data among Patients Genotyped for Antiplatelet Therapy Selection
por: Beitelshees, Amber L., et al.
Publicado: (2020)

The Role of Antiplatelet Therapy in Patients With MINOCA
por: Ortega-Paz, Luis, et al.
Publicado: (2022)

Association of soluble suppression of tumorigenicity 2 protein with new-onset atrial fibrillation in patients with acute ST-segment elevation myocardial infarction undergoing primary PCI
por: Zhao, Ting-ting, et al.
Publicado: (2023)

Diagnostic Value of Angiography-Derived IMR for Coronary Microcirculation and Its Prognostic Implication After PCI
por: Dai, Neng, et al.
Publicado: (2021)

Surgical Turned-Downed CHIP Cases—Can PCI Save the Day?
por: Achim, Alexandru, et al.
Publicado: (2022)

Short dual antiplatelet therapy and dual antiplatelet therapy de-escalation after primary percutaneous intervention: For whom and how
por: Muthspiel, Marie, et al.
Publicado: (2022)

Analysis of the Guiding Role of CYP2C19 Gene Combined With Platelet Function Detection in Antiplatelet Therapy in Patients With Complex Coronary Artery Disease After PCI
por: Yu, Jiancai, et al.
Publicado: (2022)

Drug-Coated Balloon Treatment for ACS Induced by Myocardial Bridging: An Intravascular Ultrasound-Guided PCI
por: Shen, Linghong, et al.
Publicado: (2020)

Cost-effectiveness of CYP2C19 genotyping to guide antiplatelet therapy for acute minor stroke and high-risk transient ischemic attack
por: Cai, Zeling, et al.
Publicado: (2021)

A nomogramic model for predicting the left ventricular ejection fraction of STEMI patients after thrombolysis-transfer PCI
por: Liu, Shuai, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_h6qrtu1vvcgvv5q225g46ddakb